A phase I trial studying bronticuzumab, the monoclonal antibody against Notch1, demonstrated 6 of 36 ACC subjects had either a partial or prolonged period of disease stabilization (NCT01778439) [25,64]. Here, NOTCH1 is linked to adrenal cortex carcinoma.